Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Anacor Pharmaceuticals, Inc. (ANAC) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/24/2016 8-K Quarterly results
06/08/2016 8-K Form 8-K - Current report
05/16/2016 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger among Anacor Pharmaceuticals, Inc., Pfizer Inc. and Quattro Merger Sub Inc",
"Pfizer to Acquire Anacor"
05/10/2016 8-K Form 8-K - Current report
04/06/2016 8-K Form 8-K - Current report
03/31/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF $250 MILLION OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2023"
03/30/2016 8-K Form 8-K - Current report
03/22/2016 8-K Form 8-K - Current report
02/29/2016 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS · Submitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults · Recognized $69.7 million in total KERYDIN® distribution and commercialization agreement revenues for the year ended December 31, 2015"
02/24/2016 8-K Other Events
02/05/2016 8-K Form 8-K - Current report
01/11/2016 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Investor Presentation",
"ANACOR PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CRISABOROLE TOPICAL OINTMENT, 2% FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS"
11/03/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS · Recognized $21.1 million in total KERYDIN® revenue in the third quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 18.8% over the second quarter of 2015 · Top-line results from the long-term safety study of crisaborole topical ointment, 2%, in patients with mild-to-moderate atopic dermatitis demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months · Anacor expects to submit a New Drug Application for crisaborole topical ointment, 2%, to the U.S. Food and Drug Administration in the first quarter of 2016",
"ANACOR PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM LONG-TERM SAFETY STUDY OF CRISABOROLE TOPICAL OINTMENT, 2% IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS · Crisaborole, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months · Anacor now expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first quarter of 2016"
08/21/2015 8-K Other Events
08/06/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS · Recognized $17.8 million in total KERYDIN® revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015 · Crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies in patients with mild-to-moderate atopic dermatitis and demonstrated a safety profile consistent with previous studies · Anacor expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first half of 2016"
07/13/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PHASE 3 PIVOTAL STUDIES OF CRISABOROLE TOPICAL OINTMENT, 2% IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS · Crisaborole, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically significant results on all primary and secondary endpoints in both studies and demonstrated a safety profile consistent with previous studies · Anacor expects to submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the first half of 2016 Anacor to Host a Conference Call Today at 7:30 a.m. ET / 4:30 a.m. PT to Discuss Results"
06/29/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS ANNOUNCES AMENDMENT TO KERYDIN COMMERCIALIZATION AGREEMENT"
06/11/2015 8-K Submission of Matters to a Vote of Security Holders
06/03/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Anacor pharmaceuticals NAMES GRAEME BELL AS new Executive Vice President and CHIEF FINANCIAL OFFICER Bell brings more than 20 years expertise in global finance, M&A and business development"
05/06/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
03/12/2015 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2014 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS"
01/12/2015 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Sixth Amendment to Lease, by and between Balzer Family Investments, L.P. and Anacor Pharmaceuticals, Inc"
11/06/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
10/16/2014 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, by and between Anacor Pharmaceuticals, Inc. and Wells Fargo Bank, National Association",
"Registration Rights Agreement, by and among Anacor Pharmaceuticals, Inc. and Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare Capital Partners II, L.P. and VHCP Co-Investment Holdings II, LLC"
10/09/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF $75 MILLION OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2021"
10/08/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF $70 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2021"
10/03/2014 8-K Entry into a Material Definitive Agreement
09/22/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF KERYDIN TOPICAL SOLUTION, 5% IN THE UNITED STATES"
09/12/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ANACOR PHARMACEUTICALS APPOINTS WENDELL WIERENGA TO ITS BOARD OF DIRECTORS"
08/07/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
07/21/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS AND SANDOZ ENTER INTO AN AGREEMENT FOR THE COMMERCIALIZATION OF KERYDINTM IN THE UNITED STATES Anacor Will Host a Conference Call Today at 8:00 a.m. EDT / 5:00 a.m. PDT"
07/08/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA APPROVES ANACOR PHARMACEUTICALS' KERYDIN™ TOPICAL SOLUTION, 5% FOR THE TREATMENT OF ONYCHOMYCOSIS OF THE TOENAILS"
05/30/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ANACOR PHARMACEUTICALS APPOINTS KEITH R. LEONARD, JR. TO BOARD OF DIRECTORS"
05/07/2014 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy